Products
Suvemcitug Biosimilar Monoclonal Antibody (VEGF-A) for Research
Cat No.: GMP-Bios-INN-1403
Anti-VEGFA therapeutic antibody (Pre-made Suvemcitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Suvemcitug (development codes APX003/BD0801) is a humanized monoclonal antibody targeting VEGF-A (VEGFA). It is developed by Epitomics and Jiangsu T-mab BioPharma and Simcere Pharmaceutical Group for Fallopian tube cancer, Ovarian cancer, Peritoneal cancer et al. in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1403-1mg | 1mg | 3090 |
| GMP-Bios-INN-1403-10mg | 10mg | |
| GMP-Bios-INN-1403-100mg | 100mg | |
| GMP-Bios-INN-1403-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Suvemcitug biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VEGFA/Vascular endothelial growth factor A/long form/L-VEGF therapeutic antibody |
| INN Name | Suvemcitug |
| Target | VEGFA |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Epitomics;Jiangsu T-mab BioPharma;Simcere Pharmaceutical Group |
| Conditions Approved | na |
| Conditions Active | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Colorectal cancer;Solid tumours |
| Conditions Discontinued | Wet age-related macular degeneration |
| Production | na |
| Development Tech | na |
